Pulmonary artery intimal sarcoma misdiagnosed as pulmonary embolism: MDM2 amplification as the diagnostic anchor in an unresectable tumor—a case report
Abstract Background Pulmonary artery intimal sarcoma (PAIS) is a rare and aggressive vascular malignancy whose clinical and radiological features overlap with those of pulmonary thromboembolism (PTE); most patients are initially anticoagulated, and no standard systemic therapy exists for unresectable disease. Amplification of MDM2 is the defining genomic event, yet it is usually treated as a supplementary finding rather than as a diagnostic test. Case presentation A 51-year-old man without thromboembolic risk factors presented with cough, sputum production, and chest discomfort. Contrast-enhanced computed tomography (CT) showed filling defects extending from the main pulmonary artery into both branches together with a 5.0 × 2.7 cm left upper lobe mass, and he received rivaroxaban until hemoptysis occurred. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT showed concordant hypermetabolism of the intravascular and parenchymal lesions. Two biopsies, including an expert review, narrowed the differential only to intimal sarcoma versus sarcomatoid carcinoma; next-generation sequencing then identified MDM2 amplification with CDKN2A deletion, a low tumor mutational burden (1.95 mutations/Mb), and negative PD-L1 expression, establishing MDM2-driven PAIS. Because the tumor was unresectable, he received six cycles of sintilimab, docetaxel, and cisplatin, two further cycles of sintilimab and docetaxel, consolidative intensity-modulated radiotherapy (60 Gy in 25 fractions), and maintenance sintilimab monotherapy. The best response was stable disease with a 27.9% reduction in the sum of target-lesion diameters, and progression-free survival reached 12.1 months without grade ≥3 immune-related adverse events. Conclusions When morphology and immunohistochemistry are indeterminate, MDM2 amplification can be the decisive diagnostic test rather than a supplementary finding, and it should be sought before empirical treatment is committed. Chemotherapy-primed PD-1 blockade followed by consolidative radiotherapy produced durable disease control in an immunologically cold tumor; prospective registries are needed to test this sequence.
Authors
- Hongmei Mou (ORCID: https://orcid.org/0000-0002-6624-7757)
- Xu Xi (ORCID: https://orcid.org/0009-0004-2567-616X)
- Yajie Zhu
- Xiaorong Liu
- You Wang
- Yi Wang
Institutions
- University of Electronic Science and Technology of China (CN)
- Sichuan Cancer Hospital (CN)
- Chengdu University of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-12
- DOI
- https://doi.org/10.21203/rs.3.rs-11465967/v1
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- preprint